{"protocolSection":{"identificationModule":{"nctId":"NCT02683746","orgStudyIdInfo":{"id":"200952"},"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus","officialTitle":"A Repeat-dose Study in Subjects With Type 2 Diabetes Mellitus to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics, of Albiglutide Liquid Drug Product"},"statusModule":{"statusVerifiedDate":"2019-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-03-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-04-03","type":"ACTUAL"},"completionDateStruct":{"date":"2017-05-15","type":"ACTUAL"},"studyFirstSubmitDate":"2016-01-28","studyFirstSubmitQcDate":"2016-02-11","studyFirstPostDateStruct":{"date":"2016-02-17","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-03-13","resultsFirstSubmitQcDate":"2018-04-30","resultsFirstPostDateStruct":{"date":"2018-05-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-07-10","lastUpdatePostDateStruct":{"date":"2019-07-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This is a phase III, randomized, double-blind, multicenter, parallel group, repeat-dose, study of 26 weeks duration to evaluate the efficacy, safety, tolerability and pharmacodynamic response of albiglutide liquid drug product relative to the commercial lyophilized drug product. The study will specifically evaluate the potential for immunogenicity (example \\[e.g.\\] incidences of anti-drug antibodies \\[ADA\\]) and injection site reactions (ISRs).\n\nAlbiglutide is a novel analogue of glucagon-like peptide-1 (GLP-1) with a sufficiently long half-life to permit once a week injection. Currently, lyophilized albiglutide and the diluent are provided in a dual chamber cartridge (DCC), single-dose pen injector, requiring reconstitution prior to use. A liquid formulation of albiglutide will enable the commercialization of a liquid product in a single dose, ready-to-use prefilled syringe in an auto-injector.\n\nThe primary hypothesis of this study is to test that liquid drug product will provide glycemic control (as measured by HbA1c change from baseline) non-inferior to lyophilized drug product for a period of 26 weeks of treatment in subjects with T2DM.\n\nThis study will comprise of 3 study periods : screening (2 weeks), treatment (26 weeks) and for those subjects not entering the extension study a follow-up period (8 weeks). Approximately 300 subjects will be randomized in a 1:1 ratio to either Albiglutide active liquid auto-injector (LAI) plus Placebo lyophilized DCC pen injector (lyophilized DCC PI); or, Albiglutide lyophilized DCC PI plus Placebo LAI."},"conditionsModule":{"conditions":["Diabetes Mellitus, Type 2"],"keywords":["Pharmacodynamics","Safety","Albiglutide","Tolerability","Type 2 Diabetes Mellitus","Efficacy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":308,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Albiglutide active LAI plus Placebo lyophilized DCC PI","type":"EXPERIMENTAL","description":"Subjects will receive 30 milligrams (mg) of albiglutide liquid drug product via auto injector and matching placebo via lyophilized DCC pen injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.","interventionNames":["Drug: Lyophilized albiglutide DCC pen injector matching placebo","Drug: Albiglutide liquid auto-injector"]},{"label":"Albiglutide lyophilized DCC PI plus Placebo LAI","type":"EXPERIMENTAL","description":"Subjects will receive 30mg of albiglutide lyophilized drug product via DCC pen injector and matching placebo via auto injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.","interventionNames":["Drug: Lyophilized albiglutide DCC pen injector","Drug: Albiglutide liquid auto-injector matching placebo"]}],"interventions":[{"type":"DRUG","name":"Lyophilized albiglutide DCC pen injector","description":"A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.","armGroupLabels":["Albiglutide lyophilized DCC PI plus Placebo LAI"]},{"type":"DRUG","name":"Lyophilized albiglutide DCC pen injector matching placebo","description":"A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL","armGroupLabels":["Albiglutide active LAI plus Placebo lyophilized DCC PI"]},{"type":"DRUG","name":"Albiglutide liquid auto-injector","description":"A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.","armGroupLabels":["Albiglutide active LAI plus Placebo lyophilized DCC PI"]},{"type":"DRUG","name":"Albiglutide liquid auto-injector matching placebo","description":"A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.","armGroupLabels":["Albiglutide lyophilized DCC PI plus Placebo LAI"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26","description":"Blood samples will be collected from participants at specific time points to evaluate HbA1c to monitor for potential hyperglycemia. The last measurement collected prior to the first dose of randomized study treatment was considered as Baseline value. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The analysis was performed using a mixed-effect model with repeated measures (MMRM) method. The primary analysis will include all HbA1c values collected at scheduled visits from Week 4 up to Week 26. This will include values after hyperglycemia rescue and discontinuation from investigational product. Imputation under the non-inferiority null hypothesis for missing data will be incorporated.","timeFrame":"Baseline and Week 26"}],"secondaryOutcomes":[{"measure":"Number of Participants With On-therapy Adverse Events (AEs) and Serious AEs (SAEs)","description":"An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function.","timeFrame":"Up to Week 26"},{"measure":"Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern (PCC)","description":"Chemistry parameters for which PCC values were identified were alanine aminotransferase (ALT) (if value \\>3 \\* upper limit of normal \\[ULN\\]), albumin (if value \\>5 gram/liter \\[g/L\\] above ULN or below lower limit of normal \\[LLN\\]), alkaline phosphatase (alk.phosph.) (if value \\>3\\*ULN), aspartate aminotransferase (AST) (if value \\>3\\*ULN), total bilirubin (if value \\>1.5 ULN), calcium (if value \\<1.8 or \\>3.0 millimoles per liter \\[mmol/L\\]), carbon di oxide (CO2) (if value \\<16 or \\>40 mmol/L), creatinine (if value \\>159 micromoles per liter \\[µmol/L\\]), direct bilirubin (if value \\>1.35\\*ULN), gamma glutamyl transferase (GGT) (if value \\>3\\*ULN), potassium (if value \\>0.5 mmol/L below LLN and \\>1.0 mmol/L above ULN), protein (if value \\>15 g/L above ULN or below LLN), sodium (\\>5 mmol/L below LLN or above ULN), urate (if value \\>654 µmol/L) and urea (if value \\>2\\*ULN). Number of participants with chemistry parameters of PCC at 'any visit post-Baseline' are presented.","timeFrame":"Up to Week 26"},{"measure":"Number of Participants With Hematology Parameters of PCC","description":"Hematology parameters for which PCC values were identified were hematocrit (if value \\>0.05 below LLN or \\>0.04 above ULN), Hemoglobin (Hb) (if value \\>20 g/L below LLN or \\>10 g/L above ULN), lymphocytes (if value \\<0.5\\*LLN), neutrophils (if value \\<1 giga unit per liter \\[GI/L\\]) and platelets (if value \\<80 GI/L or \\>500 GI/L). Number of participants with hematology parameters of PCC at 'any visit post-Baseline' are presented.","timeFrame":"Up to Week 26"},{"measure":"Number of Participants With Vital Signs of PCC","description":"Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate were measured in a seated position after at least 5 minutes of rest. SBP values \\<100 millimeters of mercury (mmHg) and \\>170 mmHg, DBP values \\<50 mmHg and \\>110 mmHg, pulse rate values \\<50 beats per minute (bpm) and \\>120 bpm were considered as PCC values. Number of participants with PCC values of vital signs for 'any visit post-Baseline' are presented.","timeFrame":"Up to Week 34"},{"measure":"Number of Participants With Electrocardiogram (ECG) Parameters of PCC","description":"Single measurements of 12-lead ECG were obtained in semi recumbent position using an ECG machine that automatically calculates the heart rate and measures PR and QT interval corrected for heart rate according to Fridericia's formula (QTcF). Number of participants with ECG values of PCC at 'any visit post-Baseline' are presented. ECG mean heart rate values \\<50 or \\>120, PR interval \\>300 milliseconds (msec), QRS interval \\>200 msec, QTcF interval \\>=500 msec were considered as PCC values. Number of participants with PCC values of ECG parameters for 'any visit post-Baseline' are presented.","timeFrame":"Up to Week 26"},{"measure":"Number of Participants With Positive Result for Anti-albiglutide Antibody","description":"Blood samples were obtained from participants at specific time points before administration of study treatment. The presence of anti-albiglutide antibodies was assessed using a validated enzyme linked immunosorbent assay (ELISA). The assay involves screening, confirmation, and titration steps (tiered-testing approach). Number of participants with positive anti- albiglutide antibody results at 'any visit post-Baseline' are presented.","timeFrame":"Up to Week 34"},{"measure":"Number of Participants With Injection Site Reactions (ISR)","description":"Number of participants with ISR incidences were evaluated at specific time points. Each week included those participants with the onset of an ISR during that particular week as well as those participants with ISR from previous weeks that have not resolved.","timeFrame":"Up to Week 34"},{"measure":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26","description":"Blood samples were collected from participants at specific time points to evaluate FPG to monitor for potential hyperglycemia. The last measurement collected prior to the first dose of randomized study treatment was considered as Baseline value. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The analysis was performed using a MMRM model.","timeFrame":"Baseline and Week 26"},{"measure":"Change From Baseline in HbA1c Over Time","description":"Blood samples were collected from participants at specific time points to evaluate HbA1c to monitor for potential hyperglycemia. The last measurement collected prior to the first dose of randomized study treatment was considered as Baseline value. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The analysis was performed using a MMRM model and model-adjusted least square mean (LS mean) and standard error have been presented. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).","timeFrame":"Baseline and up to Week 26"},{"measure":"Change From Baseline in FPG Over Time","description":"Blood samples were collected from participants at specific time points to evaluate FPG to monitor for potential hyperglycemia. The last measurement collected prior to the first dose of randomized study treatment was considered as Baseline value. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The analysis was performed using a MMRM model. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).","timeFrame":"Baseline and up to Week 26"},{"measure":"Trough Plasma Concentration of Albiglutide Over Time","description":"Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of albiglutide. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).","timeFrame":"Pre-dose at Week 12 and Week 26"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 to 80 years of age inclusive\n* Historical diagnosis of type 2 diabetes mellitus (T2DM) (at least 3 months), experiencing inadequate glycemic control on current regimen of diet and exercise or on a stable maximal tolerated dose of metformin, maintained for approximately 8 weeks prior to screening.\n* HbA1c \\>=7.0 percent (%) and \\<=10%.\n* Hemoglobin \\>=11 grams per deciliter (g/dL) (\\>=110 grams per liter \\[g/L\\]) for males and \\>=10 g/dL (\\>=100 g/L) for females.\n* Body mass index \\<=40 kilograms per squared meter (kg/m\\^2)\n* Male or female\n* Able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* History of cancer that has not been in full remission for at least 3 years before screening. (A history of squamous cell or basal cell carcinoma of the skin or treated cervical intra-epithelial neoplasia I or II is allowed).\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.\n* History of acute or chronic pancreatitis.\n* History of thyroid dysfunction or an abnormal (i.e., outside the normal reference range) thyroid function test assessed by thyroid stimulating hormone at screening.\n* Severe gastroparesis, i.e., requiring regular therapy within 6 months before screening.\n* History of significant gastrointestinal (GI) surgery that in the opinion of the investigator is likely to significantly affect upper GI or pancreatic function\n* History of severe hypoglycemia unawareness\n* Diabetic complications or any other clinically significant abnormality .\n* Clinically significant Cardiovascular (CV) and/or cerebrovascular disease within 3 months before screening\n* QT interval corrected for heart rate according to Fridericia's formula (QTcF) \\> 470 milliseconds (msec).\n* ALT \\>2.5x upper limit of the normal range (ULN) or bilirubin \\>1.5xULN (isolated bilirubin \\>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \\<35%).\n* Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment).\n* Estimated glomerular filtration rate (eGFR) \\<=30 milliliter (mL)/minute (min)/1.73 squared meter (m\\^2) (calculated using the Modification of Diet in Renal Disease \\[MDRD\\] formula) at screening.\n* Fasting triglyceride level \\>750 milligrams per deciliter (mg/dL) at screening.\n* Hemoglobinopathy that may affect proper interpretation of HbA1c.\n* Medical or psychiatric disorders that would preclude effective participation in study.\n* Use of oral or systemically injected glucocorticoids within the 3 months before randomization or high likelihood of a requirement for prolonged treatment (\\>1 week) in the 6 months following randomization.\n* Use of dipeptidyl peptidase-IV inhibitors within the 3 months before randomization.\n* History of alcohol or substance abuse within one year before screening.\n* Known allergy to albiglutide or any product components (including yeast and human albumin), any other glucagon-like peptide-1 (GLP-1) analogue, or other study medication's excipients OR other contraindications (per the prescribing information) for the use of potential study medications.\n* A positive pre-study drug/alcohol screen.\n* A positive test for human immunodeficiency virus (HIV) antibody.\n* The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Birmingham","state":"Alabama","zip":"35216","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"GSK Investigational Site","city":"Birmingham","state":"Alabama","zip":"35235","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"GSK Investigational Site","city":"Chandler","state":"Arizona","zip":"85224","country":"United States","geoPoint":{"lat":33.30616,"lon":-111.84125}},{"facility":"GSK Investigational Site","city":"Glendale","state":"Arizona","zip":"85306","country":"United States","geoPoint":{"lat":33.53865,"lon":-112.18599}},{"facility":"GSK Investigational Site","city":"Phoenix","state":"Arizona","zip":"85018","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"GSK Investigational Site","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"GSK Investigational Site","city":"Canyon Country","state":"California","zip":"91351","country":"United States","geoPoint":{"lat":34.42333,"lon":-118.47203}},{"facility":"GSK Investigational Site","city":"Chula Vista","state":"California","zip":"91911","country":"United States","geoPoint":{"lat":32.64005,"lon":-117.0842}},{"facility":"GSK Investigational Site","city":"Fresno","state":"California","zip":"93720","country":"United States","geoPoint":{"lat":36.74773,"lon":-119.77237}},{"facility":"GSK Investigational Site","city":"Lomita","state":"California","zip":"90717","country":"United States","geoPoint":{"lat":33.79224,"lon":-118.31507}},{"facility":"GSK Investigational Site","city":"Oceanside","state":"California","zip":"92056","country":"United States","geoPoint":{"lat":33.19587,"lon":-117.37948}},{"facility":"GSK Investigational Site","city":"Sacramento","state":"California","zip":"95821","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"GSK Investigational Site","city":"San Diego","state":"California","zip":"92120","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"GSK Investigational Site","city":"Spring Valley","state":"California","zip":"91978","country":"United States","geoPoint":{"lat":32.74477,"lon":-116.99892}},{"facility":"GSK Investigational Site","city":"Tustin","state":"California","zip":"92780","country":"United States","geoPoint":{"lat":33.74585,"lon":-117.82617}},{"facility":"GSK Investigational Site","city":"Van Nuys","state":"California","zip":"91405","country":"United States","geoPoint":{"lat":34.18667,"lon":-118.44897}},{"facility":"GSK Investigational Site","city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"GSK Investigational Site","city":"Littleton","state":"Colorado","zip":"80128","country":"United States","geoPoint":{"lat":39.61332,"lon":-105.01665}},{"facility":"GSK Investigational Site","city":"Bradenton","state":"Florida","zip":"34208","country":"United States","geoPoint":{"lat":27.49893,"lon":-82.57482}},{"facility":"GSK Investigational Site","city":"Brooksville","state":"Florida","zip":"34601","country":"United States","geoPoint":{"lat":28.55554,"lon":-82.38991}},{"facility":"GSK Investigational Site","city":"Clearwater","state":"Florida","zip":"33765-2616","country":"United States","geoPoint":{"lat":27.96585,"lon":-82.8001}},{"facility":"GSK Investigational Site","city":"Fleming Island","state":"Florida","zip":"32003","country":"United States","geoPoint":{"lat":30.0933,"lon":-81.71898}},{"facility":"GSK Investigational Site","city":"Hallandale","state":"Florida","zip":"33009","country":"United States","geoPoint":{"lat":25.9812,"lon":-80.14838}},{"facility":"GSK Investigational Site","city":"Hialeah","state":"Florida","zip":"33016","country":"United States","geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"GSK Investigational Site","city":"Miami","state":"Florida","zip":"33156","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"GSK Investigational Site","city":"Miami","state":"Florida","zip":"33176","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"GSK Investigational Site","city":"New Port Richey","state":"Florida","zip":"34652","country":"United States","geoPoint":{"lat":28.24418,"lon":-82.71927}},{"facility":"GSK Investigational Site","city":"Orlando","state":"Florida","zip":"32825","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"GSK Investigational Site","city":"St. Petersburg","state":"Florida","zip":"33709","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"GSK Investigational Site","city":"Conyers","state":"Georgia","zip":"30094","country":"United States","geoPoint":{"lat":33.66761,"lon":-84.01769}},{"facility":"GSK Investigational Site","city":"Snellville","state":"Georgia","zip":"30078","country":"United States","geoPoint":{"lat":33.85733,"lon":-84.01991}},{"facility":"GSK Investigational Site","city":"Meridian","state":"Idaho","zip":"83642","country":"United States","geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"GSK Investigational Site","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"GSK Investigational Site","city":"Elgin","state":"Illinois","zip":"60124","country":"United States","geoPoint":{"lat":42.03725,"lon":-88.28119}},{"facility":"GSK Investigational Site","city":"Evansville","state":"Indiana","zip":"47714","country":"United States","geoPoint":{"lat":37.97476,"lon":-87.55585}},{"facility":"GSK Investigational Site","city":"Topeka","state":"Kansas","zip":"66606","country":"United States","geoPoint":{"lat":39.04833,"lon":-95.67804}},{"facility":"GSK Investigational Site","city":"Lexington","state":"Kentucky","zip":"40503","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"GSK Investigational Site","city":"Lake Charles","state":"Louisiana","zip":"70601","country":"United States","geoPoint":{"lat":30.21309,"lon":-93.2044}},{"facility":"GSK Investigational Site","city":"New Orleans","state":"Louisiana","zip":"70119","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"GSK Investigational Site","city":"Kalamazoo","state":"Michigan","zip":"49009","country":"United States","geoPoint":{"lat":42.29171,"lon":-85.58723}},{"facility":"GSK Investigational Site","city":"Troy","state":"Michigan","zip":"48098","country":"United States","geoPoint":{"lat":42.60559,"lon":-83.14993}},{"facility":"GSK Investigational Site","city":"Chesterfield","state":"Missouri","zip":"63017","country":"United States","geoPoint":{"lat":38.66311,"lon":-90.57707}},{"facility":"GSK Investigational Site","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"GSK Investigational Site","city":"Las Vegas","state":"Nevada","zip":"89123","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"GSK Investigational Site","city":"Albuquerque","state":"New Mexico","zip":"87102","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"GSK Investigational Site","city":"New Hyde Park","state":"New York","zip":"11042","country":"United States","geoPoint":{"lat":40.7351,"lon":-73.68791}},{"facility":"GSK Investigational Site","city":"Greensboro","state":"North Carolina","zip":"27405","country":"United States","geoPoint":{"lat":36.07264,"lon":-79.79198}},{"facility":"GSK Investigational Site","city":"Shelby","state":"North Carolina","zip":"28150","country":"United States","geoPoint":{"lat":35.29235,"lon":-81.53565}},{"facility":"GSK Investigational Site","city":"Columbus","state":"Ohio","zip":"43201","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"GSK Investigational Site","city":"Maumee","state":"Ohio","zip":"43537-9402","country":"United States","geoPoint":{"lat":41.56283,"lon":-83.65382}},{"facility":"GSK Investigational Site","city":"Norwood","state":"Ohio","zip":"45212","country":"United States","geoPoint":{"lat":39.15561,"lon":-84.45966}},{"facility":"GSK Investigational Site","city":"Perrysburg","state":"Ohio","zip":"43551","country":"United States","geoPoint":{"lat":41.557,"lon":-83.62716}},{"facility":"GSK Investigational Site","city":"Altoona","state":"Pennsylvania","zip":"16602","country":"United States","geoPoint":{"lat":40.51868,"lon":-78.39474}},{"facility":"GSK Investigational Site","city":"Anderson","state":"South Carolina","zip":"29621","country":"United States","geoPoint":{"lat":34.50344,"lon":-82.65013}},{"facility":"GSK Investigational Site","city":"Columbia","state":"South Carolina","zip":"29204","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"GSK Investigational Site","city":"Arlington","state":"Texas","zip":"76012","country":"United States","geoPoint":{"lat":32.73569,"lon":-97.10807}},{"facility":"GSK Investigational Site","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"GSK Investigational Site","city":"Houston","state":"Texas","zip":"77051","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"GSK Investigational Site","city":"Houston","state":"Texas","zip":"77058","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"GSK Investigational Site","city":"Houston","state":"Texas","zip":"77074","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"GSK Investigational Site","city":"Katy","state":"Texas","zip":"77079","country":"United States","geoPoint":{"lat":29.78579,"lon":-95.8244}},{"facility":"GSK Investigational Site","city":"Pharr","state":"Texas","zip":"78577","country":"United States","geoPoint":{"lat":26.1948,"lon":-98.18362}},{"facility":"GSK Investigational Site","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"GSK Investigational Site","city":"San Antonio","state":"Texas","zip":"78231","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"GSK Investigational Site","city":"Schertz","state":"Texas","zip":"78154","country":"United States","geoPoint":{"lat":29.55217,"lon":-98.26973}},{"facility":"GSK Investigational Site","city":"Spring","state":"Texas","zip":"77379","country":"United States","geoPoint":{"lat":30.07994,"lon":-95.41716}},{"facility":"GSK Investigational Site","city":"Murray","state":"Utah","zip":"84123","country":"United States","geoPoint":{"lat":40.66689,"lon":-111.88799}},{"facility":"GSK Investigational Site","city":"Federal Way","state":"Washington","zip":"98003","country":"United States","geoPoint":{"lat":47.32232,"lon":-122.31262}},{"facility":"GSK Investigational Site","city":"Spokane","state":"Washington","zip":"99208","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"GSK Investigational Site","city":"Tacoma","state":"Washington","zip":"98405","country":"United States","geoPoint":{"lat":47.25288,"lon":-122.44429}}]},"referencesModule":{"references":[{"pmid":"31004676","type":"BACKGROUND","citation":"Shaddinger BC, Soffer J, Vlasakakis G, Shabbout M, Weston C, Nino A. Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2019 Jun;152:125-134. doi: 10.1016/j.diabres.2019.04.018. Epub 2019 Apr 18."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"IPD for this study will be made available via the Clinical Study Data Request site.","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"timeFrame":"IPD is available via the Clinical Study Data Request site (click on the link provided below)","accessCriteria":"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.","url":"https://www.clinicalstudydatarequest.com/SearchAllPostings.aspx?searchparam=200952"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"This repeat-dose study of albiglutide was conducted at 153 sites in the United States (US). A total of 624 participants with type 2 diabetes mellitus (T2DM) were screened; of these 316 were screen failures and 308 were randomized to receive albiglutide liquid drug product or lyophilized drug product in a 1:1 ratio.","groups":[{"id":"FG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"FG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"154"},{"groupId":"FG001","numSubjects":"154"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"138"},{"groupId":"FG001","numSubjects":"140"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"14"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"One participant was randomized to receive Albiglutide and withdrawn from the study prior to receiving any study medication for reason 'withdrew consent'.","groups":[{"id":"BG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"BG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"153"},{"groupId":"BG001","value":"154"},{"groupId":"BG002","value":"307"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57.6","spread":"9.25"},{"groupId":"BG001","value":"56.6","spread":"10.08"},{"groupId":"BG002","value":"57.1","spread":"9.67"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"79"},{"groupId":"BG002","value":"149"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"158"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Race/ethnicity customized","categories":[{"title":"American Indian (AI) or Alaska native Heritage","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}]},{"title":"Asian- Central/ South Asian Heritage","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Asian- Japanese/East Asian (EA)/South EA Heritage","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]},{"title":"Black or African American (AA) Heritage","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"39"}]},{"title":"Native Hawaiian or Other Pacific Islander Heritage","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]},{"title":"White Heritage","measurements":[{"groupId":"BG000","value":"129"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"251"}]},{"title":"Multiple- AI or Alaska Native and White Heritage","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]},{"title":"Multiple- Black or AA and White Heritage","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26","description":"Blood samples will be collected from participants at specific time points to evaluate HbA1c to monitor for potential hyperglycemia. The last measurement collected prior to the first dose of randomized study treatment was considered as Baseline value. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The analysis was performed using a mixed-effect model with repeated measures (MMRM) method. The primary analysis will include all HbA1c values collected at scheduled visits from Week 4 up to Week 26. This will include values after hyperglycemia rescue and discontinuation from investigational product. Imputation under the non-inferiority null hypothesis for missing data will be incorporated.","populationDescription":"Intent-To-Treat (ITT) Population comprised of all randomized participants who received at least one dose of study treatment and have a Baseline assessment.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percentage of total hemoglobin","timeFrame":"Baseline and Week 26","groups":[{"id":"OG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"OG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.12","spread":"0.072"},{"groupId":"OG001","value":"-1.18","spread":"0.072"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The primary hypothesis tested was that the liquid drug product would provide glycemic control non-inferior to the lyophilized drug product for a period of 26 weeks of treatment in participants with T2DM. Non-inferiority testing was performed at a one-sided alpha of 0.025 and non-inferiority margin of 0.4.","pValue":"0.0002","pValueComment":"P-value from a one-sided t-test to test whether the difference of least square means (Albiglutide liquid - Albiglutide lyophilized) is equal to the pre-specified non-inferiority margin of 0.4%.","statisticalMethod":"MMRM model","paramType":"Mean Difference (Net)","paramValue":"0.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.13","ciUpperLimit":"0.24"}]},{"type":"SECONDARY","title":"Number of Participants With On-therapy Adverse Events (AEs) and Serious AEs (SAEs)","description":"An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function.","populationDescription":"Safety Population comprised of all enrolled participants who received at least one dose of study treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participnats","timeFrame":"Up to Week 26","groups":[{"id":"OG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"OG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}]}],"classes":[{"title":"AEs","categories":[{"measurements":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"94"}]}]},{"title":"SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern (PCC)","description":"Chemistry parameters for which PCC values were identified were alanine aminotransferase (ALT) (if value \\>3 \\* upper limit of normal \\[ULN\\]), albumin (if value \\>5 gram/liter \\[g/L\\] above ULN or below lower limit of normal \\[LLN\\]), alkaline phosphatase (alk.phosph.) (if value \\>3\\*ULN), aspartate aminotransferase (AST) (if value \\>3\\*ULN), total bilirubin (if value \\>1.5 ULN), calcium (if value \\<1.8 or \\>3.0 millimoles per liter \\[mmol/L\\]), carbon di oxide (CO2) (if value \\<16 or \\>40 mmol/L), creatinine (if value \\>159 micromoles per liter \\[µmol/L\\]), direct bilirubin (if value \\>1.35\\*ULN), gamma glutamyl transferase (GGT) (if value \\>3\\*ULN), potassium (if value \\>0.5 mmol/L below LLN and \\>1.0 mmol/L above ULN), protein (if value \\>15 g/L above ULN or below LLN), sodium (\\>5 mmol/L below LLN or above ULN), urate (if value \\>654 µmol/L) and urea (if value \\>2\\*ULN). Number of participants with chemistry parameters of PCC at 'any visit post-Baseline' are presented.","populationDescription":"Safety Population. Only those participants present at 'any visit post-Baseline' are analyzed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to Week 26","groups":[{"id":"OG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"OG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"153"}]}],"classes":[{"title":"ALT; >3*ULN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Albumin; >5 g/L below LLN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Albumin; >5 g/L above ULN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Alk.phosph.; >3*ULN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"AST; >3*ULN","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Bilirubin; >1.5*ULN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Calcium; <1.8 mmol/L","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Calcium; >3.0 mmol/L","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"CO2; <16 mmol/L","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}]},{"title":"CO2; >40 mmol/L","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Creatinine; >159 µmol/L","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Direct bilirubin; >1.35ULN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"GGT; >3*ULN","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]},{"title":"Potassium; >0.5 mmol/L below LLN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Potassium; >1.0 mmol/L above ULN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Protein; >15 g/L below LLN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Protein; >15 g/L above ULN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Sodium; >5 mmol/L below LLN","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Sodium; >5 mmol/L above ULN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Urate; >654 µmol/L","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Urea; >2*ULN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Hematology Parameters of PCC","description":"Hematology parameters for which PCC values were identified were hematocrit (if value \\>0.05 below LLN or \\>0.04 above ULN), Hemoglobin (Hb) (if value \\>20 g/L below LLN or \\>10 g/L above ULN), lymphocytes (if value \\<0.5\\*LLN), neutrophils (if value \\<1 giga unit per liter \\[GI/L\\]) and platelets (if value \\<80 GI/L or \\>500 GI/L). Number of participants with hematology parameters of PCC at 'any visit post-Baseline' are presented.","populationDescription":"Safety Population. Only those participants present at 'any visit post-Baseline' are analyzed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to Week 26","groups":[{"id":"OG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"OG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"153"}]}],"classes":[{"title":"Hematocrit; >0.05 (fraction of 1) below LLN","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}]},{"title":"Hematocrit; >0.04 (fraction of 1) above ULN","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Hb; >20 g/L below LLN","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"}]}]},{"title":"Hb; >10 g/L above ULN","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Lymphocytes; <0.5*LLN","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Neutrophils; <1 GI/L","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Platelets; <80 GI/L","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Platelets; >500 GI/L","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Vital Signs of PCC","description":"Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate were measured in a seated position after at least 5 minutes of rest. SBP values \\<100 millimeters of mercury (mmHg) and \\>170 mmHg, DBP values \\<50 mmHg and \\>110 mmHg, pulse rate values \\<50 beats per minute (bpm) and \\>120 bpm were considered as PCC values. Number of participants with PCC values of vital signs for 'any visit post-Baseline' are presented.","populationDescription":"Safety Population. Only those participants present at 'any visit post-Baseline' are analyzed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to Week 34","groups":[{"id":"OG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"OG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"153"}]}],"classes":[{"title":"SBP: <100 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"16"}]}]},{"title":"SBP; >170 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"13"}]}]},{"title":"DBP; <50 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"DBP; > 110 mmHg","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"Pulse rate; < 50 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Pulse rate; > 120 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Electrocardiogram (ECG) Parameters of PCC","description":"Single measurements of 12-lead ECG were obtained in semi recumbent position using an ECG machine that automatically calculates the heart rate and measures PR and QT interval corrected for heart rate according to Fridericia's formula (QTcF). Number of participants with ECG values of PCC at 'any visit post-Baseline' are presented. ECG mean heart rate values \\<50 or \\>120, PR interval \\>300 milliseconds (msec), QRS interval \\>200 msec, QTcF interval \\>=500 msec were considered as PCC values. Number of participants with PCC values of ECG parameters for 'any visit post-Baseline' are presented.","populationDescription":"Safety Population. Only those participants present at 'any visit post-Baseline' are analyzed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to Week 26","groups":[{"id":"OG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"OG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"152"}]}],"classes":[{"title":"ECG mean heart rate; <50 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"ECG mean heart rate; >120 bpm","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"PR interval; >300 msec","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"QRS duration; >200 msec","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"QTcF interval; >=500 msec","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Positive Result for Anti-albiglutide Antibody","description":"Blood samples were obtained from participants at specific time points before administration of study treatment. The presence of anti-albiglutide antibodies was assessed using a validated enzyme linked immunosorbent assay (ELISA). The assay involves screening, confirmation, and titration steps (tiered-testing approach). Number of participants with positive anti- albiglutide antibody results at 'any visit post-Baseline' are presented.","populationDescription":"Safety Population. Only those participants present at 'any visit post-Baseline' are analyzed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to Week 34","groups":[{"id":"OG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"OG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"152"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"16"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Injection Site Reactions (ISR)","description":"Number of participants with ISR incidences were evaluated at specific time points. Each week included those participants with the onset of an ISR during that particular week as well as those participants with ISR from previous weeks that have not resolved.","populationDescription":"Safety Population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to Week 34","groups":[{"id":"OG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"OG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26","description":"Blood samples were collected from participants at specific time points to evaluate FPG to monitor for potential hyperglycemia. The last measurement collected prior to the first dose of randomized study treatment was considered as Baseline value. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The analysis was performed using a MMRM model.","populationDescription":"ITT Population. Only those participants available at Week 26 were analyzed.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Mmol/L","timeFrame":"Baseline and Week 26","groups":[{"id":"OG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"OG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"136"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.22","spread":"0.191"},{"groupId":"OG001","value":"-1.88","spread":"0.195"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"-0.34","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.83","ciUpperLimit":"0.14"}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c Over Time","description":"Blood samples were collected from participants at specific time points to evaluate HbA1c to monitor for potential hyperglycemia. The last measurement collected prior to the first dose of randomized study treatment was considered as Baseline value. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The analysis was performed using a MMRM model and model-adjusted least square mean (LS mean) and standard error have been presented. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent of total hemoglobin","timeFrame":"Baseline and up to Week 26","groups":[{"id":"OG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"OG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}]}],"classes":[{"title":"Week 4; n= 148, 149","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.045"},{"groupId":"OG001","value":"-0.54","spread":"0.046"}]}]},{"title":"Week 8; 145, 147","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"147"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":"0.057"},{"groupId":"OG001","value":"-1.02","spread":"0.057"}]}]},{"title":"Week 12; n= 137, 145","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"145"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.15","spread":"0.065"},{"groupId":"OG001","value":"-1.23","spread":"0.064"}]}]},{"title":"Week 16; n= 136, 144","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"144"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.25","spread":"0.070"},{"groupId":"OG001","value":"-1.27","spread":"0.070"}]}]},{"title":"Week 20; n= 137, 142","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.24","spread":"0.067"},{"groupId":"OG001","value":"-1.26","spread":"0.066"}]}]},{"title":"Week 26; n= 138, 141","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.16","spread":"0.071"},{"groupId":"OG001","value":"-1.17","spread":"0.071"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"Calculated P-value from a one-sided t-test to test whether the difference of least square means (Albiglutide liquid - Albiglutide lyophilized) is equal to the pre-specified non-inferiority margin of 0.4%.","statisticalMethod":"MMRM model","paramType":"Mean Difference (Net)","paramValue":"0.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.07","ciUpperLimit":"0.13","estimateComment":"Difference in HbA1c levels between albiglutide liquid and lyophilized product at Week 4 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"Calculated P-value from a one-sided t-test to test whether the difference of least square means (Albiglutide liquid - Albiglutide lyophilized) is equal to the pre-specified non-inferiority margin of 0.4%.","statisticalMethod":"MMRM model","paramType":"Mean Difference (Net)","paramValue":"0.07","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.07","ciUpperLimit":"0.20","estimateComment":"Difference in HbA1c levels between albiglutide liquid and lyophilized product at Week 8 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"Calculated P-value from a one-sided t-test to test whether the difference of least square means (Albiglutide liquid - Albiglutide lyophilized) is equal to the pre-specified non-inferiority margin of 0.4%.","statisticalMethod":"MMRM model","paramType":"Mean Difference (Net)","paramValue":"0.08","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.08","ciUpperLimit":"0.24","estimateComment":"Difference in HbA1c levels between albiglutide liquid and lyophilized product at Week 12 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"Calculated P-value from a one-sided t-test to test whether the difference of least square means (Albiglutide liquid - Albiglutide lyophilized) is equal to the pre-specified non-inferiority margin of 0.4%.","statisticalMethod":"MMRM model","paramType":"Mean Difference (Net)","paramValue":"0.02","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.16","ciUpperLimit":"0.20","estimateComment":"Difference in HbA1c levels between albiglutide liquid and lyophilized product at Week 16 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"Calculated P-value from a one-sided t-test to test whether the difference of least square means (Albiglutide liquid - Albiglutide lyophilized) is equal to the pre-specified non-inferiority margin of 0.4%.","statisticalMethod":"MMRM model","paramType":"Mean Difference (Net)","paramValue":"0.02","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.15","ciUpperLimit":"0.19","estimateComment":"Difference in HbA1c levels between albiglutide liquid and lyophilized product at Week 20 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"Calculated P-value from a one-sided t-test to test whether the difference of least square means (Albiglutide liquid - Albiglutide lyophilized) is equal to the pre-specified non-inferiority margin of 0.4%.","statisticalMethod":"MMRM model","paramType":"Mean Difference (Net)","paramValue":"0.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.17","ciUpperLimit":"0.20","estimateComment":"Difference in HbA1c levels between albiglutide liquid and lyophilized product at Week 26 are presented."}]},{"type":"SECONDARY","title":"Change From Baseline in FPG Over Time","description":"Blood samples were collected from participants at specific time points to evaluate FPG to monitor for potential hyperglycemia. The last measurement collected prior to the first dose of randomized study treatment was considered as Baseline value. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The analysis was performed using a MMRM model. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Mmol/L","timeFrame":"Baseline and up to Week 26","groups":[{"id":"OG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"OG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}]}],"classes":[{"title":"Week 1; n= 148, 144","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"144"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.04","spread":"0.165"},{"groupId":"OG001","value":"-1.29","spread":"0.167"}]}]},{"title":"Week 2; n= 143, 145","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"145"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.52","spread":"0.180"},{"groupId":"OG001","value":"-1.77","spread":"0.181"}]}]},{"title":"Week 3; n= 145, 140","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.71","spread":"0.168"},{"groupId":"OG001","value":"-1.70","spread":"0.170"}]}]},{"title":"Week 4; n= 142, 145","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"145"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.93","spread":"0.162"},{"groupId":"OG001","value":"-1.91","spread":"0.164"}]}]},{"title":"Week 5; n= 146, 143","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.04","spread":"0.160"},{"groupId":"OG001","value":"-2.23","spread":"0.162"}]}]},{"title":"Week 6; n= 145, 145","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"145"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.07","spread":"0.167"},{"groupId":"OG001","value":"-2.22","spread":"0.169"}]}]},{"title":"Week 7; n= 146, 144","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"144"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.93","spread":"0.176"},{"groupId":"OG001","value":"-2.20","spread":"0.179"}]}]},{"title":"Week 8; n= 143, 141","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.19","spread":"0.169"},{"groupId":"OG001","value":"-2.38","spread":"0.171"}]}]},{"title":"Week 9; n= 142, 141","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"141"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.05","spread":"0.178"},{"groupId":"OG001","value":"-2.08","spread":"0.180"}]}]},{"title":"Week 10; n= 141, 142","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"142"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.03","spread":"0.173"},{"groupId":"OG001","value":"-2.17","spread":"0.175"}]}]},{"title":"Week 11; n= 141, 139","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"139"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.01","spread":"0.181"},{"groupId":"OG001","value":"-2.12","spread":"0.184"}]}]},{"title":"Week 12; n= 137, 137","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.16","spread":"0.176"},{"groupId":"OG001","value":"-2.19","spread":"0.178"}]}]},{"title":"Week 13; n= 140, 136","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.04","spread":"0.202"},{"groupId":"OG001","value":"-2.09","spread":"0.205"}]}]},{"title":"Week 16; n= 140, 140","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"140"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.02","spread":"0.189"},{"groupId":"OG001","value":"-2.09","spread":"0.191"}]}]},{"title":"Week 20; n= 139, 134","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.87","spread":"0.197"},{"groupId":"OG001","value":"-1.90","spread":"0.201"}]}]},{"title":"Week 26; n= 141, 136","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.22","spread":"0.191"},{"groupId":"OG001","value":"-1.88","spread":"0.195"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.15","ciUpperLimit":"0.65","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 1 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.25","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.20","ciUpperLimit":"0.69","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 2 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"-0.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.42","ciUpperLimit":"0.40","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 3 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"-0.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.42","ciUpperLimit":"0.36","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 4 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.19","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.19","ciUpperLimit":"0.57","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 5 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.15","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.26","ciUpperLimit":"0.55","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 6 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.27","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.16","ciUpperLimit":"0.71","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 7 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.19","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.22","ciUpperLimit":"0.60","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 8 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.41","ciUpperLimit":"0.47","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 9 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.15","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.28","ciUpperLimit":"0.57","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 10 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.11","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.34","ciUpperLimit":"0.56","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 11 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.41","ciUpperLimit":"0.46","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 12 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.05","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.47","ciUpperLimit":"0.57","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 13 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.41","ciUpperLimit":"0.54","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 16 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"0.03","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.47","ciUpperLimit":"0.53","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 20 are presented."},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Mean Difference (Net)","paramValue":"-0.34","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.83","ciUpperLimit":"0.14","estimateComment":"Difference in FPG levels between albiglutide liquid and lyophilized product at Week 26 are presented."}]},{"type":"SECONDARY","title":"Trough Plasma Concentration of Albiglutide Over Time","description":"Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of albiglutide. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).","populationDescription":"PK Population","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Nanograms per milliliter (ng/mL)","timeFrame":"Pre-dose at Week 12 and Week 26","groups":[{"id":"OG000","title":"Albiglutide Liquid","description":"Eligible participants received 30 milligrams (mg) of albiglutide active liquid auto-injector along with placebo lyophilized dual chamber cartridge (DCC) pen injector once weekly for 4 weeks by subcutaneous (SC) injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."},{"id":"OG001","title":"Albiglutide Lyophilized","description":"Eligible participants received 30 mg of albiglutide active lyophilized DCC pen injector along with placebo liquid auto-injector once weekly for 4 weeks by SC injection in the abdomen, thigh, or upper arm. After 4 weeks, albiglutide dose was up-titrated to 50 mg for the remaining 22 weeks of the study treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"149"}]}],"classes":[{"title":"Week 12; n= 127, 130","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"130"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3996.9","spread":"1613.02"},{"groupId":"OG001","value":"3927.1","spread":"1537.45"}]}]},{"title":"Week 26; n= 127, 127","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4196.6","spread":"1500.57"},{"groupId":"OG001","value":"3929.1","spread":"1338.08"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"On-therapy SAEs and non-SAEs are presented from the start of study treatment up to Week 26.","description":"On-therapy SAEs and non-SAEs are reported for the safety Population, comprised of all enrolled participants who received at least one dose of study treatment.","eventGroups":[{"id":"EG000","title":"Albiglutide Active LAI Plus Placebo Lyophilized DCC PI","description":"Subjects will receive 30 milligrams (mg) of albiglutide liquid drug product via auto injector and matching placebo via lyophilized DCC pen injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.","deathsNumAffected":0,"deathsNumAtRisk":153,"seriousNumAffected":7,"seriousNumAtRisk":153,"otherNumAffected":101,"otherNumAtRisk":153},{"id":"EG001","title":"Albiglutide Lyophilized DCC PI Plus Placebo LAI","description":"Subjects will receive 30mg of albiglutide lyophilized drug product via DCC pen injector and matching placebo via auto injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.","deathsNumAffected":0,"deathsNumAtRisk":154,"seriousNumAffected":9,"seriousNumAtRisk":154,"otherNumAffected":94,"otherNumAtRisk":154}],"seriousEvents":[{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Spindle cell sarcoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Squamous cell carcinoma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Lumbar spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]}],"otherEvents":[{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":153},{"groupId":"EG001","numAffected":20,"numAtRisk":154}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":153},{"groupId":"EG001","numAffected":10,"numAtRisk":154}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":153},{"groupId":"EG001","numAffected":5,"numAtRisk":154}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":5,"numAtRisk":154}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":4,"numAtRisk":154}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Otitis externa","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Acarodermatitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Acute sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Gingivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Groin abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Incision site abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Otitis media chronic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Papilloma viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Pharyngitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Post procedural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Vaginal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Viraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Vulvovaginal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":153},{"groupId":"EG001","numAffected":25,"numAtRisk":154}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":153},{"groupId":"EG001","numAffected":11,"numAtRisk":154}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":153},{"groupId":"EG001","numAffected":6,"numAtRisk":154}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":153},{"groupId":"EG001","numAffected":6,"numAtRisk":154}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":6,"numAtRisk":154}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":153},{"groupId":"EG001","numAffected":3,"numAtRisk":154}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":3,"numAtRisk":154}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":3,"numAtRisk":154}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Abdominal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Epigastric discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Irritable bowel syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Tongue ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Tooth impacted","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":153},{"groupId":"EG001","numAffected":3,"numAtRisk":154}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":153},{"groupId":"EG001","numAffected":5,"numAtRisk":154}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":153},{"groupId":"EG001","numAffected":3,"numAtRisk":154}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":3,"numAtRisk":154}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Exostosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Intervertebral disc degeneration","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Joint effusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Joint range of motion decreased","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Neuropathic arthropathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Osteoporosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Pain in jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Plantar fasciitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Tendon sheath disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Tendonitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":153},{"groupId":"EG001","numAffected":6,"numAtRisk":154}]},{"term":"Injection site bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":153},{"groupId":"EG001","numAffected":5,"numAtRisk":154}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":7,"numAtRisk":154}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":5,"numAtRisk":154}]},{"term":"Injection site rash","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":153},{"groupId":"EG001","numAffected":3,"numAtRisk":154}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":3,"numAtRisk":154}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Injection site discolouration","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Injection site haematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Injection site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Injection site irritation","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Vaccination site bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Vessel puncture site haematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Vessel puncture site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":153},{"groupId":"EG001","numAffected":14,"numAtRisk":154}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":153},{"groupId":"EG001","numAffected":6,"numAtRisk":154}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Diabetic neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Nerve compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Periodic limb movement disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Tension headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":153},{"groupId":"EG001","numAffected":5,"numAtRisk":154}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":153},{"groupId":"EG001","numAffected":5,"numAtRisk":154}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":4,"numAtRisk":154}]},{"term":"Paranasal sinus discomfort","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Lower respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Allergic bronchitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Allergic sinusitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Pharyngeal ulceration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Tonsillar hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Upper-airway cough syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Vasomotor rhinitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":3,"numAtRisk":154}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":5,"numAtRisk":154}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":4,"numAtRisk":154}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":3,"numAtRisk":154}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Abdominal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Arthropod sting","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Burns second degree","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Extradural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Facial bones fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Joint injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Patella fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Procedural complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Skin injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Skull fractured base","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Tendon injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":153},{"groupId":"EG001","numAffected":6,"numAtRisk":154}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Hyperphagia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Vitamin D deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Diabetic ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Ingrowing nail","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Intertrigo","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Lichen planus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Skin mass","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":153},{"groupId":"EG001","numAffected":7,"numAtRisk":154}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":3,"numAtRisk":154}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Attention deficit/hyperactivity disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Binge eating","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Borderline personality disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Libido decreased","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":153},{"groupId":"EG001","numAffected":5,"numAtRisk":154}]},{"term":"Food allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Left ventricular hypertrophy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Mitral valve calcification","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":2,"numAtRisk":154}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Age-related macular degeneration","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Blepharitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Conjunctival haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Erythema of eyelid","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Breast tenderness","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Oligomenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Vaginal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Heart sounds abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Liver function test increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Motion sickness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]},{"term":"Papillary thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":153},{"groupId":"EG001","numAffected":0,"numAtRisk":154}]},{"term":"Bladder spasm","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":153},{"groupId":"EG001","numAffected":1,"numAtRisk":154}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","email":"GSKClinicalSupportHD@gsk.com","phone":"866-435-7343"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2016-05-26","uploadDate":"2018-01-30T01:49","filename":"Prot_000.pdf","size":1043941},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2017-07-14","uploadDate":"2018-01-30T01:50","filename":"SAP_001.pdf","size":769048}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]}},"hasResults":true}